\n \;
\n Camilo Zapata (Alkerm
es) | \n Abstract:
Business analytics is the &ldquo\;discipline&rdquo\; in charge of
identifying and leveraging meaningful patterns in data to drive or inform
business decisions. It is multidisciplinary in nature as it operates at t
he intersection between mathematics/statistics\, computer science and mana
gement. \; In this talk we will discuss how these three areas converge
to deliver impactful results and share some relevant examples. We will al
so talk about what characteristics an organization requires in order to le
verage this discipline as in the business world the ability to impact deci
sions is not only determined by the quality of the analyses\, but also the
robustness of the processes\, the skills of the decision makers and the a
pproachability of the results. \;
\n
\n
Bio: Camilo is a data scientist that currently leads t
he advance analytics organization at Alkermes. He focuses on everything th
at is not clinical\, with special emphasis on the commercial side of the b
usiness. \; Before Alkermes he led the compliance analytics efforts at
Pfizer and the Text mining and Natural language processing hub at Lilly.&
nbsp\; He also co-led the creation of the advanced business analytics grou
p at Lilly and he was responsible for building the analytical capabilities
of Lilly&rsquo\;s clinical trial supply chain organization.\n
Camilo is an engineer by training with M.S. degrees in Chemical and ind
ustrial engineering and a PhD in Chemical engineering from Purdue Universi
ty. In spite of these titles is fair to say that as an engineer he wouldn&
rsquo\;t survive. \n | \n \n \n
\n Helena Baptista (Lilly) | \n
Abstract: \;We have been measuring the
efficacy and safety of our medicines for a long time. What are we doing to
measure the efficacy of our promotional strategies? Developing great medi
cines is key\, but if we fail to let the scientific community know when an
d why they should use our products\, patients that would benefit the most
will hardly get access to them. We need to provide directions to the marke
ting teams on how\, when and how often to reach the interested health care
providers. On top\, in Europe\, we need to do that with limited access to
data. We will discuss what we can do and where do we have the biggest cha
llenges.
\n
\n Bio: \;\n \n - Education: PhD in statistics. NO
VA University of Lisbon &ndash\; Portugal
\n - Profes
sional experience: Finance\, Market Research\, Operations management\, For
ecasting\, Advanced Commercial Analytics (actual)
\n Teaching undergraduates and Mastery courses on Forecasting Methods and S
tatistics for Enterprise Data Analysis\n \n
| \n
\n \n \;
\n Lucy Frit
h (GSK) \; | \n Abstract:&n
bsp\;Working with a commercial organisation provides a varied array of tas
ks that often need complex analyses explained in a very concise but transp
arent way. This can lead to re-use of study data to present the results in
a manner that meets the specific needs of different external groups such
as health care professional (HCPs). Two such examples will be presented he
re. Firstly\, overlaying the costs of treatments and patient care onto pat
ient outcomes to support discussions with payer groups. Secondly\, using M
arkov Chain modelling to utilise long-term data and provide Health care pr
ofessionals a presentation of the data that aligns to the probability of a
patient changing health status in a given period of time. To give further
context to how these presentations of data could be used\, such work is r
eviewed using data collected in a traditional efficacy study and in a prag
matic effectiveness situation.
\n
\n
Bio: Lucy is currently working in the late phase respiratory
research and supports a range of marketed products. She has a keen interes
t in re-using data appropriately to maximise the value of information coll
ected during the development of a medicine. This is to further understand
the products\, the disease areas of interest and presenting this informati
on in a practical way to external groups such as health care professional
(HCPs). \; \;\n Lucy is a statistician with 26 years
&rsquo\; experience in the industry\; where she has been involved in the c
linical program design\, taking products all the way through to submission
and regulatory approval. She has a M.S. degrees in Medical Statistics and
a MBA. \n | \n
\n